AsciertoPASchadendorfDBerkingCAgarwalaSSvan HerpenCMQueiroloPBlankCUHauschildABeckJTSt-PierreA. 2013. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14(3):249–256.
2.
BrownNARollandDMcHughJBWeigelinHCZhaoLLimMSElenitoba-JohnsonKSBetzBL. 2014. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 20(21):5517-5526.
3.
ByronSAGartsideMPowellMAWellensCLGaoFMutchDGGoodfellowPJPollockPM. 2012. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 7(2):e30801.
4.
ChenHMaJLiWEliseenkovaAVXuCNeubertTAMillerWTMohammadiM. 2007. Molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell. 27(5):717–730.
5.
GardnerDGHeikinheimoKShearMPhilipsenHPColemanH. 2005. Ameloblastomas. In: BarnesLEvesonJWReichartPSidranskyD, editors. Pathology and genetics of head and neck tumours (IARC WHO Classification of Tumours). Lyon, France: IARC Press. p. 296–300.
6.
HeikinheimoKKurppaKJLaihoAPeltonenSBerdalABouattourARuhin-PoncetBCatónJThesleffILeivoI. 2015. Early dental epithelial transcription factors distinguish ameloblastoma from keratocystic odontogenic tumor. J Dent Res. 94(1):101–111.
7.
HolderfieldMDeukerMMMcCormickFMcMahonM. 2014. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 14(7):455–467.
8.
KimDJKimJSpaunhurstKMontoyaJKhodoshRChandraKFuTGilliamAMolgoMBeachyPA. 2014. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 32(8):745–751.
9.
KimJAftabBTTangJYKimDLeeAHRezaeeMKimJChenBKingEMBorodovskyA. 2013. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 23(1):23–34.
10.
KurppaKJCatónJMorganPRRistimäkiARuhinBKellokoskiJEleniusKHeikinheimoK. 2014. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 232(5):492–498.
11.
LemmonMASchlessingerJ. 2010. Cell signaling by receptor tyrosine kinases. Cell. 141(7):1117–1134.
12.
LiTJ. 2011. The odontogenic keratocyst: a cyst, or a cystic neoplasm?J Dent Res. 90(2):133–142.
13.
LiYMangasarianKMansukhaniABasilicoC. 1997. Activation of FGF receptors by mutations in the transmembrane domain. Oncogene. 14(12):1397–1406.
14.
MenziesAMLongGV. 2014. Systemic treatment for BRAF-mutant melanoma: where do we go next?Lancet Oncol. 15(9):e371–e381.
15.
PrahalladASunCHuangSDi NicolantonioFSalazarRZecchinDBeijersbergenRLBardelliABernardsR. 2012. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 483(7387):100–103.
16.
SweeneyRTMcClaryACMyersBRBiscochoJNeahringLKweiKAQuKGongXNgTJonesCD. 2014. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 46(7):722–725.
